<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588937</url>
  </required_header>
  <id_info>
    <org_study_id>361HBV15017</org_study_id>
    <nct_id>NCT02588937</nct_id>
  </id_info>
  <brief_title>Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT.
      in chronic hepatitis B Patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 300copies/mL)</measure>
    <time_frame>48 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 300copies/mL)</measure>
    <time_frame>24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference between the baseline and at the 24, 48 week of HBV DNA level(log10)</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg serum loss</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg seroconversion</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg serum loss</measure>
    <time_frame>48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg seroconversion</measure>
    <time_frame>48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed Virologic breakthrough</measure>
    <time_frame>12, 24, 48 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>EntecaBell ODT.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude Tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EntecaBell ODT. 0.5mg</intervention_name>
    <arm_group_label>EntecaBell ODT.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude Tab. 0.5mg</intervention_name>
    <arm_group_label>Baraclude Tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over the age of 20 years old

          2. Patients with Chronic Hepatitis B diagnosed

          3. Patients who show positive HBsAg

          4. Patients who show positive HBeAg or negative HBeAg

          5. Patients who showed HBV DNA undetected(less than 300 copies/mL)

          6. Patients who have administered Baraclude Tab. 0.5mg for 1~4 years

          7. Patients who showed ALT less than 5 times of the upper limit in the normal range

          8. Patient who decided to participate and signed on an informed consent form willingly

        Exclusion Criteria:

          1. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency
             virus (HIV)

          2. Patients with a uncompensated liver disease who have at least one of the following
             values or signs

               -  Total bilirubin &gt; 2.5mg/dl

               -  Prothrombin time delayed more than three seconds of upper limit in the normal
                  range

               -  Serum Albumin &lt; 3 g/dL

               -  A medical history of ascites, jaundice, hemorrhage by varix, hepatic
                  encephalopathy, or other signs of liver function loss

          3. Patients who are estimated to have hepatocellular carcinoma (HCC) through imaging
             examination or showed alpha-fetoprotein(AFP) more than 100 ng/mL

          4. Patients who showed Creatinine Clearance &lt; 50 mL/min by calculating Cockcroft-Gault
             equation

          5. Patients who were not administered any anti-viral agents except Baraclude
             Tab.(Entecavir)

          6. Administration of other Investigational Product within 30 days

          7. History of malignant tumor within 5 years (including leukemia and lymphoma)

          8. Patients who have a severe disease, such as heart failure, renal failure, and
             pancreatitis, decided by an investigator to have an effect on this clinical trial

          9. Patients who have other hepatic diseases except hepatitis B

         10. Administration immunosuppressants or corticosteroids over 2 weeks within 24 weeks

         11. Patients who have to administer immunosuppressants or Nephrotoxic drugs, Hepatotoxic
             drugs for period of Clinical Trial

         12. Pregnant, breast-feeding and childbearing age who don't use adequate contraception

         13. Patients who are possible to decline daily function due to a mental disease or
             patients who are not able to understand the purpose and methods of this clinical trial

         14. Patients who received an organ transplant or are going to received an organ transplant

         15. Severe hypersensitivity to Entecavir

         16. Another clinical condition in investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Chungju Hospital</name>
      <address>
        <city>Chungju</city>
        <state>Chungcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>ChungCheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Chungcheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeong sangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Entecavir, EntecaBell ODT., Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

